Market Place
Sourcing Support
Phase 3 Allele Study Confirms Tabelecleucel`s Efficacy In EBV+ PTLD
07 Dec 2024 //
PR NEWSWIRE
Fernando Junoy Named Pierre Fabre’s International Director
31 Oct 2024 //
PRESS RELEASE
Pierre Fabre Doses First Patient In PFL-002 Phase I/II For NSCLC
24 Oct 2024 //
PR NEWSWIRE
Jubilant Biosys signs partnership with Pierre Fabre SA
10 Oct 2024 //
EXPRESSPHARMA
Pierre And Scorpion Dose First Patient In PFL-241 Trial Lung Cancer
08 Oct 2024 //
BUSINESSWIRE
Pierre Fabre, Scorpion Start Phase I/II Oncology Trial
07 Oct 2024 //
PRESS RELEASE
Jubilant Biosys signs & Issues Put Option Offer To Pierre Fabre
06 Oct 2024 //
INDPHARMAPOST
FDA Grants Priority Review For Pierre Fabre`s Tabelecleucel BLA
18 Jul 2024 //
PR NEWSWIRE
Pierre Fabre Signs Sponsorship Deal With IHU HealthAge In Toulouse
12 Jul 2024 //
PRESS RELEASE
Pierre Fabre Laboratories Announce European Authorization For OBGEMSA
28 Jun 2024 //
PR NEWSWIRE
Pierre Fabre`s Obgemsa (vibegron) Receives Approval In Europe
27 Jun 2024 //
EMA
Pierre Fabre receives the Galien International Prize for EBVALLO®
21 Jun 2024 //
PRESS RELEASE
Green Bioplastics Project " wins 1st prize in the Maud Fontenoy Foundation
13 Jun 2024 //
PRESS RELEASE
Pierre Fabre Laboratories Awarded Responsible Digital Label
05 Jun 2024 //
PRESS RELEASE
Pierre Fabre: IND For PFL-002/VERT-002 In Solid Tumors With MET Mutations
05 Jun 2024 //
PR NEWSWIRE
Pierre Fabre: Positive CHMP Opinion for OBGEMSA™ in OAB
26 Apr 2024 //
PR NEWSWIRE
Pierre Fabre Appoints Adriana Herrera CEO of New U.S. Affiliate
04 Apr 2024 //
CONTRACT PHARMA
Pierre Fabre Study 5% Of Population Affected By Rosacea
28 Mar 2024 //
PRESS RELEASE
Pierre Fabre presents first global study on epidemiology of acne.
19 Mar 2024 //
PRESS RELEASE
Kinnate Sells Pan-RAF Inhibitor Exarafenib To Pierre Fabre
05 Mar 2024 //
PRESS RELEASE
Kinnate Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre
01 Mar 2024 //
GLOBENEWSWIRE
Pierre Fabre Pursues Innovative Therapies For Rare Pediatric Diseases
29 Feb 2024 //
PRESS RELEASE
Pierre Fabre committed to combating rare pediatric diseases via therapies
23 Feb 2024 //
PR NEWSWIRE
Pierre Fabre & EspeRare awarded for patient engagement approach
16 Feb 2024 //
PRESS RELEASE
Pierre Fabre and the EspeRare Foundation to be honored with the EURORDIS Award
15 Feb 2024 //
PR NEWSWIRE
Atara and Pierre Fabre Announce Publication of Phase 3 ALLELE Tab-cel® Data
31 Jan 2024 //
BUSINESSWIRE
Eau Thermale Avene Hits €1B Turnover Bolsters Medical Focus
23 Jan 2024 //
PRESS RELEASE
Pierre Fabre Collaborates With Chowis Company
24 Nov 2023 //
ACCESSWIRE
Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories
15 Nov 2023 //
BUSINESSWIRE
Pierre Fabre commits up to $640M in T-cell deal with Atara
04 Nov 2023 //
FIERCE PHARMA
EMA validates Pierre Fabre`s MAA for BRAFTOVI
02 Nov 2023 //
PR NEWSWIRE
Scorpion and Pierre Announce First Patient Dosed in Phase 1/2 Trial of STX-721
10 Oct 2023 //
PR NEWSWIRE
Pierre Fabre and Vernalis announce a drug discovery collaboration in oncology
25 Sep 2023 //
PR NEWSWIRE
Pierre Fabre Laboratories Acquires Vertical Bio
12 Sep 2023 //
PR NEWSWIRE
Pierre Fabre consolidates unique expertise in dermatology by creating database
20 Jun 2023 //
PRESS RELEASE
Pierre Fabre Inaugurates Its New Innovation Center In China
09 Jun 2023 //
PRESS RELEASE
Terran announces exclusive licensing deal with Pierre Fabre for idazoxan
02 Jun 2023 //
PR NEWSWIRE
Pierre Fabre announces the acquisition of MÊME
12 Apr 2023 //
PRESS RELEASE
Scorpion and Pierre Announce Collaboration to Co-Develop STX-721 and STX-241
04 Apr 2023 //
BUSINESSWIRE
Pierre Fabre`s Ebvallo (tabelecleucel) Receives Approval in Europe
10 Mar 2023 //
EMA
Pierre Fabre`s Ebvallo (Tabelecleucel) Approved In Europe
16 Feb 2023 //
EMA
Pierre Fabre to Commercialize Approved Allogeneic T-cell Immunotherapy in Europe
08 Feb 2023 //
BUSINESSWIRE
Pierre Fabre pursues commitment against rare diseases in the pediatric fields.
06 Feb 2023 //
PR NEWSWIRE
HealthCare Royalty pays Atara $31M cash for a piece of cell therapy royalties
21 Dec 2022 //
ENDPTS
Bormioli Pharma and Pierre Fabre are developing 100% recycled PET packaging
25 Oct 2022 //
PRESS RELEASE
CHMP offers +ve opinion for two high-profile drugs- latest batch recommendations
15 Oct 2022 //
ENDPTS
Pierre Fabre is taking a minority stake, via its invest Pierre Fabre Invest
10 Oct 2022 //
FIRSTWORLDPHARMA
Pierre Fabre becomes first industrial group labeled at the "Exemplary" level
28 Sep 2022 //
PRESS RELEASE
Atara to Receive Payment Under Updated Tab-cel Agreement with Pierre Fabre
28 Sep 2022 //
PRESS RELEASE
Changes within the Group Management Committee
21 Sep 2022 //
PRESS RELEASE
Maud Vimeux joins the Pierre Fabre Group as Deputy Managing Director
05 Sep 2022 //
PRESS RELEASE
Urovant and Pierre Fabre Sign Excl. License Agreement to Commercialize Vibegron
06 Jul 2022 //
BUSINESSWIRE
Pierre Fabre and the EspeRare administer investigational treatment for XLHED
02 Jul 2022 //
PRNEWSWIRE
Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Ab Drug Product
16 Jun 2022 //
PRNEWSWIRE
Emergence strengthens leadership team with the appointment of Hatem Azim as CMO
07 Jun 2022 //
GLOBENEWSWIRE
EORTC and Pierre Fabre launch phase 3 trial for melanoma
27 May 2022 //
PMLIVE
First patient enrolled in melanoma study
25 May 2022 //
PHARMAFILE
Pierre Fabre, 60 Years Of Caring For Everyone
24 May 2022 //
PRESS RELEASE
Pierre Fabre & EORTC open a large Phase III clinical study the adjuvant setting
24 May 2022 //
PRESS RELEASE
1962-2022: THE PIERRE FABRE GROUP CELEBRATES ITS 60TH ANNIVERSARY
23 May 2022 //
PRESS RELEASE
